Cryoport, Inc. (Cryoport), is a life sciences services company that is an integral part of the supply chain supporting the biopharma, reproductive medicine and animal health markets. Through its products and services, the Company enables its clients to ship, store and deliver cellular-based materials and drug products as well as other life sciences commodities in a precise, defined temperature-controlled state. The Company’s advanced platform is comprised of comprehensive and technology-centric systems and solutions are designed to support the global high-volume distribution of commercial biologic and cell-based products and therapies regulated by the United States Food and Drug Administration (FDA) and other international regulatory bodies for distribution in the Americas, Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions. The Company’s subsidiaries include Cryoport Systems, Inc., MVE Biological Solutions, CRYOPDP and Cryogene Partners.
During the most recent quarter, 830K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.